Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Cyxone AB","sponsor":"Professor Rikard Holmdahl","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyxone Signs Agreement With Professor Rikard Holmdahl as Senior Scientific Advisor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Cyxone AB"},{"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Cyxone AB"},{"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo\u2019s Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Orexo"},{"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patent Issued in Europe for Orexo's Adrenaline Product OX640","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Orexo"}]

Orexo

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

First Patent Issued in Europe for Orexo's Adrenaline Product OX640

Details:

OX640 is nasal adrenaline rescue medication based on the amorphOX® drug delivery platform is a unique and innovative new product to be used for the emergency treatment of allergic reactions.

Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: OX640

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 01, 2022

ASK
US

Upload
your Pipeline Activity

Orexo

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Orexo’s Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development

Details:

Stability data generated so far for OX640 (adrenaline) strongly indicates the potential for an adrenaline product with significantly improved stability versus today's injection products, both in terms of allowed storage temperatures as well as shelf-life.

Lead Product(s): Epinephrine

Therapeutic Area: Immunology Product Name: OX640

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 05, 2022

ASK
US

Upload
your Pipeline Activity

Cyxone AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Details:

While Cyxone continues to develop the oral administration form for T20K, the company has also decided to initiate a feasibility study on a subcutaneous administration form in Q2 2021. Finally, biomarker development to support both administration forms will be completed.

Lead Product(s): T20K

Therapeutic Area: Immunology Product Name: T20K

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2021

ASK
US

Upload
your Pipeline Activity

Cyxone AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cyxone Signs Agreement With Professor Rikard Holmdahl as Senior Scientific Advisor

Details:

The agreement will support Cyxone to develop their drug candidates T20K and Rabeximod and bring them closer to the market.

Lead Product(s): T20K

Therapeutic Area: Immunology Product Name: T20K

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Professor Rikard Holmdahl

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 08, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY